Zinc, Vitamin E, Vitamin C and Beta-Carotene: study protocols
34 study groups took Zinc together with Vitamin E, Vitamin C and Beta-Carotene. These are the doses the studies gave. They are not a recommendation.
Dose per serving from research: Zinc
34 study groups in 29 studies say how much Zinc participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 10 mg to 25 mg, 53% of 34 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg or less | 1 |
| 10 mg to 25 mg | 18 |
| 25 mg to 50 mg | 3 |
| 50 mg to 100 mg | 11 |
| over 100 mg | 1 |
Dose per serving from research: Vitamin E
20 study groups in 19 studies say how much Vitamin E participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 25 mg to 50 mg, 55% of 20 study groups.
| Daily dose | Study groups |
|---|---|
| 10 mg to 25 mg | 4 |
| 25 mg to 50 mg | 11 |
| 50 mg to 100 mg | 0 |
| 100 mg to 250 mg | 2 |
| 250 mg to 500 mg | 1 |
| 500 mg to 1 g | 2 |
Dose per serving from research: Vitamin C
32 study groups in 28 studies say how much Vitamin C participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 100 mg to 250 mg, 50% of 32 study groups.
| Daily dose | Study groups |
|---|---|
| 100 mg to 250 mg | 16 |
| 250 mg to 500 mg | 15 |
| over 500 mg | 1 |
Dose per serving from research: Beta-Carotene
29 study groups in 25 studies say how much Beta-Carotene participants took a day.
These are the doses the studies gave. They are not a recommendation.
Most common: 5 mg to 10 mg, 55% of 29 study groups.
| Daily dose | Study groups |
|---|---|
| 5 mg to 10 mg | 16 |
| 10 mg to 25 mg | 12 |
| over 25 mg | 1 |
Commonly used together
32 of 34 study groups took Zinc, Vitamin E, Vitamin C and Beta-Carotene with something else. Shown: what 3 or more different studies gave.
What was given together, not what works together.
| Taken with | Study groups |
|---|---|
| Selenium | 18 |
| Copper | 10 |
34 study groups
| Study | ||||||
|---|---|---|---|---|---|---|
| Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis 2016 · combination of antioxidants and zinc · Adults aged 55 years and older with age-related macular degeneration; eyes with advanced disease at baseline and participants with no AMD in both eyes were excluded | 80 mg | 400 IU | 500 mg | 15 mg | 2409 days | — |
| "The SU.VI.MAX Study": a primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers. SUpplementation on VItamines et Minéraux AntioXydants 1999 · antioxidant vitamins and minerals supplementation · Women aged 35 to 60 years and men aged 45 to 60 years, without a stated condition | 20 mg | 30 mg | 120 mg | 6 mg | 8 years | — |
| A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8 2001 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration Categories 2–4 and visual acuity of 20/32 or better in at least one eye | 80 mg | 400 IU | 500 mg | 15 mg | 8 years | — |
| Associations of mortality with ocular disorders and an intervention of high-dose antioxidants and zinc in the Age-Related Eye Disease Study: AREDS Report No. 13 2004 · antioxidants plus zinc · Adults aged 55–81 years with AMD categories 2–4 and AREDS ocular eligibility | 80 mg | 400 IU | 500 mg | 15 mg | 339 weeks | — |
| The SU.VI.MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals 2004 · antioxidant supplement group · French women aged 35–60 and men aged 45–60 in the general population | 20 mg | 30 mg | 120 mg | 6 mg | 2739 days | — |
| Antioxidant status and risk of cancer in the SU.VI.MAX study: is the effect of supplementation dependent on baseline levels? 2005 · daily antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 20 mg | 30 mg | 120 mg | 6 mg | 2739 days | — |
| [The SU.VI.MAX study, a randomized, placebo-controlled trial on the effects of antioxidant vitamins and minerals on health] 2006 · antioxidant supplementation · Middle-aged adults in the general population | 20 mg | 30 mg | 120 mg | 6 mg | 2738 days | — |
| Antioxidant supplementation increases the risk of skin cancers in women but not in men 2007 · antioxidant group · French adult women and men in a general-population primary-prevention trial | 20 mg | 30 mg | 120 mg | 6 mg | 2738 days | — |
| Incidence of cancers, ischemic cardiovascular diseases and mortality during 5-year follow-up after stopping antioxidant vitamins and minerals supplements: a postintervention follow-up in the SU.VI.MAX Study 2010 · antioxidant supplementation · French women aged 35–60 years and men aged 45–60 years | 20 mg | 30 mg | 120 mg | 6 mg | 2738 days | — |
| Long-term effects of vitamins C and E, β-carotene, and zinc on age-related macular degeneration: AREDS report no. 35 2013 · Antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration (AREDS categories 1–4) | 80 mg | 400 IU | 500 mg | 15 mg | 339 weeks | — |
| No clinically significant association between CFH and ARMS2 genotypes and response to nutritional supplements: AREDS report number 38 2014 · antioxidants plus zinc · Adults with intermediate age-related macular degeneration in one or both eyes or late age-related macular degeneration in one eye; mean age 69 years | 80 mg | 400 IU | 500 mg | 15 mg | 9 years | — |
| Effect of micronutrient supplementation on infection in institutionalized elderly subjects: a controlled trial 1997 · combination of trace elements and vitamins · Institutionalized elderly subjects in a geriatric center; low serum vitamin C, zinc and selenium were common at baseline | 20 mg | 15 mg | 120 mg | 6 mg | 2 years | — |
| Effect of a mixture of micronutrients, but not of bovine colostrum concentrate, on immune function parameters in healthy volunteers: a randomized placebo-controlled study 2006 · Colostrum + Micronutrients · Healthy, non-smoking men and women aged 40–80 years | 15 mg | 200 mg | — | — | 10 weeks | 35 |
| Effect of a mixture of micronutrients, but not of bovine colostrum concentrate, on immune function parameters in healthy volunteers: a randomized placebo-controlled study 2006 · Micronutrients · Healthy, non-smoking men and women aged 40–80 years | 15 mg | 200 mg | — | — | 10 weeks | 31 |
| The effects of antioxidant vitamin supplementation on expiratory flow rates at rest and during exercise 2015 · antioxidant vitamin supplementation (AVS) · healthy nonsmoking adults, 5 men and 5 women, consuming fewer than 5 servings of fruit and vegetables per day | 7.5 mg | 400 IU | 500 mg | 15,000 IU | 4 weeks | 10 |
| French adults' cognitive performance after daily supplementation with antioxidant vitamins and minerals at nutritional doses: a post hoc analysis of the Supplementation in Vitamins and Mineral Antioxidants (SU.VI.MAX) trial 2011 · antioxidant supplementation · French adults aged 45–60 years enrolled in the SU.VI.MAX study | 20 mg | 30 mg | 120 mg | 6 mg | 2922 days | — |
| Combination oral antioxidant supplementation reduces blood pressure 1997 · antioxidants · Hypertensive and normotensive adult outpatients; 21 were attending for hypertension treatment and 17 were normotensive outpatients with minor gastrointestinal complaints. | 200 mg | 600 mg | 500 mg | 30 mg | 8 weeks | — |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel half-dose (single softgel) · Healthy adults aged 18–45 years, women and men | 34.8 mg | — | 226 mg | 8.6 mg | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · softgel full-dose (two softgels) · Healthy adults aged 18–45 years, women and men | 69.6 mg | — | 452 mg | 17.2 mg | 1 day | 15 |
| Bioavailability of AREDS1 micronutrients from softgel capsules and tablets: a pilot study 2014 · tablet full-dose (four tablets) · Healthy adults aged 18–45 years, women and men | 69.6 mg | 400 mg | 452 mg | 17.2 mg | 1 day | 15 |
| Effect of two years' supplementation with natural antioxidants on vitamin and trace element status biomarkers: preliminary data of the SU.VI.MAX study 2001 · Antioxidant supplementation group · Women aged 35–60 years and men aged 45–60 years in France, general population | 20 mg | 30 mg | 120 mg | 6 mg | 2 years | — |
| Changes in serum retinol, alpha-tocopherol, vitamin C, carotenoids, xinc and selenium after micronutrient supplementation during alcohol rehabilitation 2003 · micronutrient supplement group · Alcohol-dependent patients aged 20 to 60 years without severe liver disease, hospitalized for alcohol rehabilitation | 20 mg | 30 mg | 120 mg | 6 mg | 3 weeks | — |
| Effect of 6 month supplementation with different combinations of an association of antioxidant nutrients on biochemical parameters and markers of the antioxidant defence system in the elderly. The Geriatrie/Min.Vit.Aox Network 1996 · VT (vitamins associated with trace elements) · Elderly nursing-home residents aged 65–103 years who were long-term hospitalized | 20 mg | 15 mg | 120 mg | 6 mg | 26 weeks | — |
| Effect of a two-year supplementation with low doses of antioxidant vitamins and/or minerals in elderly subjects on levels of nutrients and antioxidant defense parameters 1997 · mineral and vitamin group · Hospitalized adults older than 65 years; baseline deficiencies of vitamin C, zinc and selenium were common | 20 mg | 15 mg | 120 mg | 6 mg | 2 years | — |
| Effects of trace element and/or vitamin supplementation on vitamin and mineral status, free radical metabolism and immunological markers in elderly long term-hospitalized subjects. Geriatric Network MIN. VIT. AOX 1997 · trace elements associated with vitamins · Institutionalized elderly subjects in long-term hospital or nursing-home care | 20 mg | 15 mg | 120 mg | 6 mg | 1 year | — |
| Effects of supplementation with a combination of antioxidant vitamins and trace elements, at nutritional doses, on biochemical indicators and markers of the antioxidant system in adult subjects 1998 · supplementation group · Adult men aged 45–60 years and women aged 35–60 years | 20 mg | 30 mg | 120 mg | 6 mg | 26 weeks | — |
| Oxidative stress in humans during work at moderate altitude 1999 · antioxidant mixture group · U.S. Marines engaged in moderate-altitude cold-weather field training; age and sex not reported | 30 mg | — | 500 mg | — | 4 weeks | 15 |
| Effect of antioxidant supplementation on urine and blood markers of oxidative stress during extended moderate-altitude training 1999 · antioxidant supplement (S) group · US Marine Corps volunteers undergoing 14 days of winter training at approximately 2700 m | 30 mg | 400 IU | 500 mg | 20,000 IU | 2 weeks | — |
| Alterations of the lipid profile after 7.5 years of low-dose antioxidant supplementation in the SU.VI.MAX Study 2005 · antioxidant supplementation · French adults: women aged 35–60 years and men aged 45–60 years | 20 mg | 30 mg | 120 mg | 6 mg | 2738 days | — |
| Effects of long-term zinc supplementation on plasma thiol metabolites and redox status in patients with age-related macular degeneration 2007 · antioxidants plus zinc · Adults aged 55–80 with age-related macular degeneration | 80 mg | 400 IU | 500 mg | 15 mg | 2433 days | — |
| Antioxidant micronutrients and biomarkers of oxidative stress and inflammation in colorectal adenoma patients: results from a randomized, controlled clinical trial 2010 · antioxidant micronutrient combination · Patients with a history of sporadic colorectal adenoma; age and sex not specified | 60 mg | 800 mg | 1 g | 24 mg | 120 days | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS antioxidants plus zinc · Adults aged 55–80 with early or more advanced age-related macular degeneration | 80 mg | 400 IU | 500 mg | 15 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 80 mg | 400 IU | 500 mg | 15 mg | 5 years | — |
| Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration 2025 · AREDS2 original AREDS formulation with low zinc · Adults aged 50–85 with large drusen in both eyes or late AMD in one eye and large drusen in the fellow eye who accepted the additional AREDS formulation | 25 mg | 400 IU | 500 mg | 15 mg | 5 years | — |